Skip to main content

Table 2 Differentially expressed genes between BRAFwt and BRAFmut PTCs and TN samples

From: Effect of BRAFmutational status on expression profiles in conventional papillary thyroid carcinomas

Gene name

Gene symbol

BRAFwt PTC vs. BRAFmut PTC

BRAFwt PTC vs. TN

BRAFmut PTC vs. TN

  

FC1

P

FC1

P

FC1

P 2

keratin 19

KRT19

-4.39

1.3E-09

2.37

2.0E-04

10.43

8.5E-13

potassium voltage-gated channel, shaker-related subfamily, beta member 1

KCNAB1

7.66

6.4E-09

3.23

5.5E-04

-2.37

5.7E-03

solute carrier family 26, member 4

SLC26A4

7.59

4.3E-08

2.14

2.9E-02

-3.55

4.0E-04

TBC1 domain family, member 2

TBC1D2

-2.39

4.4E-08

2.71

1.0E-07

6.48

3.3E-14

tumor protein D52-like 1

TPD52L1

-2.46

3.2E-07

2.22

3.6E-05

5.46

1.1E-11

TP53 apoptosis effector

PERP

-2.09

3.6E-07

2.97

6.9E-09

6.22

1.6E-14

Periplakin

PPL

-2.53

1.0E-06

2.92

1.9E-06

7.41

2.3E-12

growth differentiation factor 15

GDF15

-5.08

1.5E-06

2.41

1.1E-02

12.23

6.8E-09

deltex homolog 4 (Drosophila)

DTX4

-3.31

3.5E-06

3.28

5.6E-05

10.86

8.4E-11

death-associated protein kinase 2

DAPK2

-2.45

1.0E-05

2.78

2.1E-05

6.83

7.6E-11

ethanolamine kinase 2

ETNK2

-2.51

1.9E-05

2.02

3.0E-03

5.07

1.3E-08

solute carrier family 34 (sodium phosphate), member 2

SLC34A2

-4.75

2.2E-05

8.86

2.2E-06

42.09

1.9E-11

transmembrane protein 98

TMEM98

-2.09

2.8E-05

2.24

9.8E-05

4.69

6.2E-10

gamma-glutamylcyclotransferase

GGCT

-2.52

3.1E-05

2.48

3.7E-04

6.26

2.3E-09

purine nucleoside phosphorylase

PNP

-3.55

3.4E-05

2.48

6.6E-03

8.82

4.7E-08

protein S (alpha)

PROS1

-2.80

3.7E-05

5.78

1.4E-07

16.18

2.8E-12

FERM domain containing 4B

FRMD4B

2.50

3.7E-05

5.04

7.3E-08

2.01

3.1E-03

mucin 1, cell surface associated

MUC1

-2.29

5.6E-05

2.23

6.8E-04

5.12

6.6E-09

protein tyrosine phosphatase, receptor type, E

PTPRE

-2.22

6.0E-05

2.45

1.3E-04

5.43

1.5E-09

gamma-aminobutyric acid (GABA) A receptor, beta 2

GABRB2

-4.73

8.6E-05

2.82

1.7E-02

13.32

3.0E-07

metastasis associated in colon cancer 1

MACC1

-2.34

1.2E-04

2.15

2.3E-03

5.02

4.0E-08

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1

CITED1

-3.58

3.4E-04

2.56

1.8E-02

9.17

1.1E-06

laminin, beta 3

LAMB3

-3.13

3.4E-04

2.46

1.2E-02

7.70

6.7E-07

syndecan 4

SDC4

-2.22

4.3E-04

4.25

1.6E-06

9.45

1.2E-10

family with sequence similarity 129, member A

FAM129A

-2.21

4.3E-04

2.27

1.9E-03

5.03

9.8E-08

fibronectin 1

FN1

-2.60

4.9E-04

10.31

8.2E-09

26.78

1.5E-12

phosphodiesterase 5A, cGMP-specific

PDE5A

-2.82

7.1E-04

6.06

6.7E-06

17.11

6.5E-10

dual specificity phosphatase 5

DUSP5

-2.11

7.9E-04

2.16

3.1E-03

4.57

2.8E-07

chitinase 3-like 1 (cartilage glycoprotein-39)

CHI3L1

-4.45

8.5E-04

3.50

1.4E-02

15.59

1.8E-06

cathepsin H

CTSH

-2.63

9.2E-04

5.31

1.1E-05

13.97

1.2E-09

trefoil factor 3 (intestinal)

TFF3

3.81

1.5E-05

-2.86

2.6E-02

-10.92

5.4E-06

met proto-oncogene (hepatocyte growth factor receptor)

MET

-2.27

2.7E-11

8.93

1.3E-08

20.25

4.6E-12

  1. 1FC, fold change; -, downregulated in BRAFwt PTCs vs. BRAFmut PTCs, downregulated in BRAFwt PTCs vs. TN, and downregulated in BRAFmut PTCs vs. TN; 2p-value with FDR < 0.05 and fold change cutoff > 2